


Galderma and Metvix® Meeting the future challenges for the treatment of non-melanoma skin cancer

Humberto C. Antunes
CEO Galderma Laboratories




Cryotherapy for AK





Surgery for BCC








GALDERMA



*Committed to the future of dermatology,
Galderma offers innovative therapeutic
solutions that improve the quality of life of
dermatology patients.*



Galderma Worldwide




Global Presence



GALDERMA









Population
Age
Structure:
1980 and
2025
(In millions)

South America

1980



2025







Population
Age
Structure:
1980 and
2025
(In millions)

North America

1980



2025



U.S. Cases of AK and BCC on the Rise

58 mil
AK

United States




1.2 mil
BCC

Source: The Lewin Group, Inc.




BCC Cases Europe + Australia



Source: European Dermatology Forum




Nodular BCC: 5-Year Recurrence Rates Metvix® vs. Surgery




Metvix® in Actinic Keratosis

Patient preference




Metvix® in BCC

Patient preference



Metvix® Around the World



Bowen disease Metvix® PDT 2 cycles

Before



After



OTHER CASES WITH Metvix® PDT...

before Metvix® PDT



3 months after



Shift in Dermatology Practice

Medical Dermatologist


- Skin disease treatment
- Prescriptions
- Limited procedures



Shift in Dermatology Practice

Corrective Dermatology

- Still treating skin diseases
- More emphasis on correction and procedures
- Lots of procedures including photodynamic therapy





Take Home Messages



- Aging population and dermatologists anxious for new non-invasive treatments like Metvix®
- Galderma has a proven track record as a worldwide dermatology leader to launch and market Metvix®
- Tremendous market opportunity

